The Phase 3 clinical trial showed that the drug, called CC-486, significantly improved survival in older patients, over the age of 55, with AML — ScienceDaily

A landmark paper published today in the New England Journal of Medicine describes the results from a global trial across 148 sites in 23 countries, showing a 30 per cent improvement in survival in patients with acute myeloid leukemia (AML). The Phase 3 clinical trial called QUAZAR, showed that a drug, called CC-486, significantly improved […]